Eric Hodgins joins Precision Medicine Group as CITO
Precision Medicine Group Names Pharma Services Innovator, Eric Hodgins, as Chief Information and Technology Officer
Industry veteran with a 30-year track record in building award-winning clinical and commercial technologies, Hodgins will focus on developing and enriching transformative technologies across Precision’s R&D and commercial services
BETHESDA, Md., April 16, 2025 – Precision Medicine Group (Precision), a leading provider of next-generation drug development, CRO and commercialization services, today announced the appointment of Eric Hodgins as the company’s Chief Information and Technology Officer, overseeing all of the company’s technology assets. (more…)
Pharma’s ‘Best-Kept Secret’
Our CEO, Margaret Keegan, is featured in the December issue of Pharmaceutical Executive candidly discussing the future of clinical development, the changing commercialization sector and the manufacturing of tomorrow’s medicines.
(more…)
Precision Medicine Group Announces Key Leadership Appointments
Karl Deonanan appointed Chief Financial Officer
Matt DeZee named to newly established role, Chief Transformation and Strategy Officer
Bethesda, Md., October 23, 2024—Precision Medicine Group (Precision), a leading next-generation provider of drug development and commercialization services, today announced key leadership changes to support its next phase of growth. This includes the appointment of Karl Deonanan as Chief Financial Officer (CFO). Mr. Deonanan succeeds Matt DeZee, who has served as CFO of Precision since 2020 and will be transitioning to the newly created role of Chief Transformation and Strategy Officer (CTSO), effective immediately.
Precision Medicine Group Welcomes Margaret Keegan as CEO
— Founding CEO Mark Clein named Executive Chairman; Mr. Clein and co-founder Ethan Leder to continue as Board Directors —
BETHESDA, MD., October 1, 2024 – Precision Medicine Group (Precision), a leading next-generation provider of drug development and commercialization services, today announced the appointment of Margaret Keegan as Chief Executive Officer (CEO) and member of the Board of Directors, effective immediately. Ms. Keegan succeeds Mark Clein, who is assuming the role of Executive Chairman. Mr. Clein co-founded Precision in 2012 as CEO and, together with co-founder Ethan Leder, purpose-built Precision to capitalize on the scientific and technological innovations that are transforming drug development and enabling widespread access to new, breakthrough therapies. Mr. Leder formerly served as Executive Chairman and will remain a member of the Board of Directors.
Now Available On Demand: Cell & Gene Day, 2024
Cell and gene therapies are at a pivot point. These breakthrough therapies show big promise — but the business models to support these new advances are racing to catch up with the science. Can we keep up the pace in the current climate? Find out at Cell & Gene Day 2024, a free virtual event, WATCH ON DEMAND HERE.